市場調査レポート

商品コード

1593536

CAR-T細胞療法の市場規模・シェア・成長分析 (製品別、標的別、適応症別、人口動態別、エンドユーザー別、地域別)：産業予測 (2024～2031年)

CAR T-Cell Therapy Market Size, Share, Growth Analysis, By Product (Yescarta, Kymriah), By Target (CD19, BCMA), By Indication, By Demographic, By End User, By Region - Industry Forecast 2024-2031

出版日: 2024年11月14日
発行: SkyQuest
ページ情報: 英文 197 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のCAR-T細胞療法の市場規模は、2022年に52億米ドルと評価され、2023年の72億7,000万米ドルから2031年には1,060億6,000万米ドルに成長し、予測期間 (2024～2031年) に39.80%のCAGRで成長する見通しです。

世界のがんの流行は、今後数年間でCAR-T細胞療法の需要を大きく牽引すると予測されています。細胞調査への投資増加や遺伝子工学技術の進歩により、CAR-T細胞療法市場は力強い成長が見込まれています。個別化医療が重視されるようになったことで、特に血液がんを適応症とするCAR-T細胞治療の需要がさらに高まる可能性が高く、この分野のサービス事業者には新たなビジネスチャンスがもたらされます。さらに、さまざまな慢性疾患を対象とした革新的なCAR-T細胞治療の承認頻度が高まっていることも、世界規模での市場拡大の可能性を裏付けています。しかし、治療費の高騰、安全性や副作用への懸念、患者へのアクセス制限などの課題もあります。CAR-T細胞療法の可能性を最大限に引き出し、より広範な患者集団に確実に行き渡らせるためには、こうした阻害要因に対処することが重要です。このような状況の進展に伴い、市場情勢の利害関係者は、技術進歩やがん領域での医療上のアンメットニーズの拡大によってもたらされる新たな機会を活用しながら、これらの課題を乗り越えていかなければなりません。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
中東・アフリカ (MEA)
- 湾岸協力会議 (GCC) 諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング (2023年)
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア (2023年)

主要企業プロファイル

Novartis AG (スイス)
Johnson & Johnson (米国)
JW (Cayman) Therapeutics Co. Ltd. (ケイマン諸島)
Immunoadoptive Cell Therapy Private Limited (Immunoact) (インド)
Carsgen Therapeutics Holdings Limited (中国)
IASO Biotherapeutics (中国)
Guangzhou Bio-Gene Technology Co., Ltd (Hedy Group Co., Ltd.) (中国)
Cartesian Therapeutics, Inc. (米国)
Autolus Therapeutics (英国)
Allogene Therapeutics (米国)
Crispr Therapeutics (スイス)
Wugen (米国)
Sangamo Therapeutics, Inc. (米国)
Bluebird Bio, Inc. (米国)
TCR2 Therapeutics Inc. (米国)
Genocea Biosciences, Inc. (米国)
Blairex Laboratories, Inc. (米国)
Medigene AG (ドイツ)
Athenex, Inc. (米国)
Zymeworks Inc. (カナダ)
Regenxbio Inc. (米国)

Product Code: SQMIG35H2300

Global CAR T-Cell Therapy Market size was valued at USD 5.2 billion in 2022 and is poised to grow from USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031).

The global cancer epidemic is anticipated to significantly drive the demand for CAR T-cell therapy in the upcoming years. With rising investments in cell research and advancements in genetic engineering technologies, the CAR T-cell therapy market is poised for robust growth. The increasing emphasis on personalized medicine is likely to further propel demand for CAR T-cell treatments, particularly in addressing blood cancer indications, which presents new opportunities for service providers in this field. Additionally, the growing frequency of approvals for innovative CAR T-cell therapies aimed at various chronic conditions underscores the expanding market potential on a global scale. However, the market faces challenges, including the high costs associated with treatment, concerns regarding procedural safety and potential side effects, as well as limited accessibility for patients. Addressing these restraints will be critical for unlocking the full potential of CAR T-cell therapies and ensuring they reach broader patient populations. As the landscape evolves, stakeholders in the CAR T-cell therapy market must navigate these challenges while capitalizing on emerging opportunities presented by technological advancements and increasing unmet medical needs in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Car T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Car T-Cell Therapy Market Segmental Analysis

Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Demographic, End User, and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other Products. Based on Target, the market is segmented into CD19, BCMA, and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia, and Other Indications. Based on Demographic, the market is segmented into Adults, and Pediatrics. Based on End User, the market is segmented into Hospitals, Specialty Centers, and Long-Term Care Facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Car T-Cell Therapy Market

The surge in personalized medicine is a significant market driver for the Global CAR T-Cell Therapy market, as it aligns closely with the growing demand for tailored healthcare solutions. As patients increasingly seek individualized treatment options, the ability of CAR T-cell therapy to be customized for each patient's unique tumor characteristics enhances its efficacy and appeal. This personalization not only improves therapeutic outcomes but also fosters patient engagement and adherence to treatment protocols. Consequently, the broader acceptance and integration of personalized medicine within oncology are expected to propel the CAR T-cell therapy market, leading to innovative advancements and expanding clinical applications in the coming years.

Restraints in the Global Car T-Cell Therapy Market

One significant market restraint for the Global CAR T-Cell Therapy market is the lingering uncertainty surrounding the long-term safety and potential side effects associated with this innovative treatment. Despite rigorous testing, concerns about adverse reactions, such as cytokine release syndrome and neurotoxicity, can lead to apprehension among patients and healthcare providers, ultimately hindering widespread adoption. Additionally, the complexity of administering CAR T-cell therapy and the requirement for specialized medical personnel and infrastructure further complicate its integration into standard cancer treatment protocols. This combination of safety concerns and logistical challenges may slow the growth of the CAR T-cell therapy market over the forecast period.

Market Trends of the Global Car T-Cell Therapy Market

The global CAR T-cell therapy market is witnessing a significant trend towards the development of allogeneic therapies, which utilize genetically modified T-cells derived from healthy donors rather than the patient's own cells. This innovation is driven by the potential for off-the-shelf treatment options that can provide quicker, more accessible solutions for patients with hematologic malignancies and solid tumors. With advancements in gene-editing technologies and the growing emphasis on reducing manufacturing complexities and costs, allogeneic CAR T-cell therapies are expected to gain traction, fostering increased investment and collaboration within the biopharmaceutical landscape. This shift promises to enhance patient outcomes while expanding market reach.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Value Chain Analysis
Technology Analysis
Patent Analysis
Pricing Analysis
Regulatory Landscape
Customer & Buying Criteria Analysis

Car T-Cell Therapy Market by Product

Market Overview
Yescarta
Kymriah
Carvykti
Abecma
Tecartus
Breyanzi
Other Products

Car T-Cell Therapy Market by Target

Market Overview
CD19
BCMA
Other Targets

Car T-Cell Therapy Market by Indication

Market Overview
Multiple Myeloma
B-Cell Lymphoma
Acute Lymphoblastic Leukemia
Other Indications

Car T-Cell Therapy Market by Demographic

Market Overview
Adults
Pediatrics

Car T-Cell Therapy Market by End User

Market Overview
Hospitals
Specialty Centers
Long-Term Care Facilities

Car T-Cell Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JW (Cayman) Therapeutics Co. Ltd. (Cayman Islands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunoadoptive Cell Therapy Private Limited (Immunoact) (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carsgen Therapeutics Holdings Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IASO Biotherapeutics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Bio-Gene Technology Co., Ltd (Hedy Group Co., Ltd.) (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cartesian Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Autolus Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allogene Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Crispr Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wugen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TCR2 Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genocea Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blairex Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigene AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athenex, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

CAR-T細胞療法の市場規模・シェア・成長分析 (製品別、標的別、適応症別、人口動態別、エンドユーザー別、地域別)：産業予測 (2024～2031年)

CAR T-Cell Therapy Market Size, Share, Growth Analysis, By Product (Yescarta, Kymriah), By Target (CD19, BCMA), By Indication, By Demographic, By End User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

分析手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

CAR-T細胞療法市場：製品別

CAR-T細胞療法市場：標的別

CAR-T細胞療法市場：適応症別

CAR-T細胞療法市場：人口動態別

CAR-T細胞療法市場：エンドユーザー別

CAR-T細胞療法市場：地域別